Prolific Machines Selected to Join FDA's Emerging Technology Program, Advancing the Company’s Novel Biomanufacturing Platform
Prolific Machines, a biotechnology company revolutionizing biologics manufacturing, announced today that it has been accepted into the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Emerging Technology Program. This highly competitive program supports the development of innovative technologies that have the potential to transform therapeutics manufacturing.
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
Prolific Machines, the Photomolecular platform leader, today announced the appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director. Meissonnier will leverage his more than 26 years of deep pharmaceutical and life science services expertise to help leading life science innovators leverage Prolific Machines’ platform and its expertise.
Prolific Machines Announces the Completion of Optogenetic Bioproduction at 200L, Marking the World’s Largest Demonstration of Optogenetics to Date
Prolific Machines, the Photomolecular platform leader, announced the world’s largest demonstration of optogenetics to date. The 200-liter run was completed at Prolific’s Emeryville, CA pilot production facilities by the company’s expert team of bioprocessing, optogenetic, hardware, and machine learning experts. Not only does this mark a significant scientific achievement, but supports Prolific’s ability to deliver commercial-scale biomanufacturing solutions to prospective partners, from early-stage biotechs to leading pharmaceutical makers.
Prolific Machines Announces the Appointment of Former Forge Biologics Executive, Christina Perry, as CFO Setting the Stage for Optogenetics Leader’s Biopharmaceutical Commercial Ramp Up
Prolific Machines, a biotechnology company using light to control biology, announces the appointment of Christina Perry to its expert team. Christina Perry joins Prolific as CFO where she will be charged with scaling Prolific’s growth and financial systems as it continues to focus on expanding its commercial reach. Perry will also leverage her deep pharmaceutical and CDMO expertise to help Prolific achieve its ambitious business goals.
Prolific Machines Receives Grant to Develop a Platform to Produce Affordable Monoclonal Antibodies to Prevent Infectious Disease in Low- and Middle-Income Countries
Prolific Machines, a biotechnology innovator harnessing light to deliver unprecedented cellular control, has received a grant from the Bill & Melinda Gates Foundation to leverage its pioneering platform to produce more affordable mAbs. The company’s technology has the potential to reduce mAb production costs while enhancing product quality, making these drugs more accessible and affordable for the prevention of infectious diseases like malaria, HIV, and RSV in LMICs.
Prolific Machines to Harness Light to Deliver Unprecedented Cellular Control, Enabling Higher Quality and Never-Before-Possible Biosolutions — Beginning a New Era of Biotechnology
Prolific Machines, the photomolecular biology innovator ushering in a new era of biotechnology by growing and controlling cells with light, today announces it has closed an initial round of $55M Series B financing, including convertible notes, for a total of $86.5M in funding to date. This first close was led by Ki Tua Fund, the corporate venture arm of Fonterra Co-operative Group, with participation from Breakthrough Energy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Robert Downey Jr’s Footprint Coalition Ventures, Conti Ventures, In-Q-Tel (IQT), Matthew Katz, and several others.
Prolific Machines Raises $42M From Top Planetary Health Investors to Build the Assembly Line for Biology
Prolific Machines, a next generation biotechnology company, is emerging from stealth today by announcing their massively oversubscribed Seed and Series A financings, led by the best VCs in the space. The Seed round was led by Arvind Gupta at Mayfield, the first investor in cultured meat. The Series A was led by Bill Gates-founded Breakthrough Energy Ventures. Prolific’s first check was written in late 2020, when SOSV’s IndieBio led their Pre-Seed round.
